SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ABT - Abbott Labs -- Ignore unavailable to you. Want to Upgrade?


To: Frostman who wrote (284)6/19/2000 2:04:00 PM
From: Skywatcher  Respond to of 328
 
Abbott Labs to market Vivus impotence drugs overseas
MOUNTAIN VIEW, Calif., June 19 (Reuters) - Drugmaker Vivus Inc. (NasdaqNM:VVUS - news) announced on Monday a distribution and marketing agreement granting Abbott Laboratories Inc. (NYSE:ABT - news) rights to its impotence drugs Muse and Alibra in select markets, including Europe, Japan, Australia, and South America.
Abbott also has the option to co-develop and license future Vivus transurethral products for the treatment of male erectile dysfunction in those overseas markets.
Muse is a small, single-use disposable plastic applicator that dispenses the drug alprostadil to increase blood flow to the penis. Alibra, a second-generation version of the drug that can be dosed at home, is awaiting regulatory approval in the United States and Europe.
Vivus previously had a pact with AstraZeneca PLC to market Muse, but the British pharmaceutical company withdrew from
the pact last October saying that the April 6, 1999, merger of Astra AB and Zeneca Group PLC to form AstraZeneca led to a change in product strategies.
Vivus markets the drug in the United States, while Muse is approved for marketing in 39 countries.
Excellent news...one way or the other they will be getting monies for an ED drug.
chris



To: Frostman who wrote (284)6/23/2000 9:54:00 AM
From: Skywatcher  Read Replies (1) | Respond to of 328
 
worldlyinvestor.com Sector of the Day A Twofer Biotech Deal
By Nadine Wong, Biotech Stocks Columnist
Sangstat and SuperGen are biotechs that are still lukewarm in a sector that's begun to boil again.
The latest economic data indicates that the Fed may have finally put the brakes on the economy. But just like Goldilocks, the market is still looking for numbers that show that inflation is not too hot, not too cold, but
``just right.''
So which stocks do you want to own in these times? The answer is biotechs, of course. There are companies that have not participated in the general market rally, but could surge on their strong fundamentals, like Sangstat Nasdaq:SANG - news) and SuperGen (Nasdaq:SUPG - news).
There are companies and sectors that will feel the slowdown more than others and you don't want to get caught in those stocks when investors start to worry whether earnings are going to fall short of projections.
Prevents Organ Grinding
Sangstat has a great product pipeline specializing in the prevention of organ rejection in transplant patients. Although the company hasn't made a profit, misperceptions of its legal problems with Novartis (NYSE:NVS - news), which I've written about before (http://www.worldlyinvestor.com/index.cfm?fuseaction=main&silo=search&depth=
searchform.cfm&article_id=5259), is mostly to blame for the stock price remaining stagnant. Sangstat's major product is
cyclosporine, the leading immunosuppressive drug used to prevent graft rejection in transplants.
In the US alone, annual sales of cyclosporine amount to $480 million. No wonder Novartis wants to protect its turf. However, Sangstat is winning the legal battles and penetrating the market with its generic version of the drug.
Sales are improving with products like Thymoglobulin and SangCya liquid that are available in both the US and Europe.
Sangstat also has a major alliance in place with Abbott (NYSE:ABT - news) for Gengraf gel capsules along with the recent approval the company should approach profitability in the year 2001.
Besides Novartis, Sangstat's only other competitor is Eon Labs and the company has yet to launch their own cyclosporine capsule, which was approved in January 2000. So far, I believe that the Abbott/SangStat alliance still has the competitive edge with a strong sales force.
Tipping Lilly Over
Another company that I believe that has the potential to do well in this environment is SuperGen, the company's pipeline should begin to bear fruit in 2001. SuperGen's key strengths are its experienced management, an alliance with Abbot, $140 million in cash on hand and a deep product pipeline.
What piques my interest is SuperGen's key drug, Rubitecan for pancreatic cancer, which has great potential. Rubitecan is expected to be approved early next year.
Pancreatic cancer kills approximately 29,000 Americans annually, and is the fourth-leading cause of cancer deaths. The current treatment of choice for pancreatic cancer is Gemzar, which is marketed by Eli Lilly (NYSE:LLY - news) and generated revenue of $455.8 million in 1999.
Currently, SuperGen is conducting three separate Phase III trials for Rubitecan. One of the trials is the Rubitecan versus Gemzar comparison in patients who have not undergone chemotherapy.
If the clinical trials favor SuperGen, the company would have a huge competitive advantage over Eli Lilly. In addition, Rubitecan's once-daily oral formulation, mild side effect profile and anti-tumor activity could propel Rubitecan above the competition.
To Have and to Hold
Right now, the market has overlooked Sangstat and SuperGen, but that's okay in my book, as I consider both of them as buys. You can hold onto the stock and anticipate growth even in times of an economic slowdown. Unlike other sectors that are either economic or interest-rate sensitive, such as consumer-oriented companies, biotech companies are not dependent upon borrowing cost.
Instead, their key funding sources are from collaborations, under which meeting milestones triggers payments, secondary
offerings of its stock, government grants, licensing agreements and revenue sharing of commercialized products.
The nice warm summer rally for biotechs hasn't pulled back yet, especially for the genomic-related companies and those
companies that have products that are producing revenue and earnings. Nevertheless, this year has been a wild ride for
biotechs with many companies' charts looking like roller coasters -- going up and up starting late last year and falling haplessly in March and beyond.
How long the current rally will last, that I cannot predict, but a slowing economy won't dampen the demand for medicines.
Nadine Wong is editor and publisher of the BioTech Navigator Newsletter (http://www.biotechnav.com), the leading
biotech investment newsletter in the nation. Her weekly column looks at the hottest stocks in the biotech sector. Wong currently has a position in Sangstat. Positions may change at any time.
more publicity the better



To: Frostman who wrote (284)6/28/2000 2:18:00 PM
From: Skywatcher  Respond to of 328
 
Preliminary Data Support Further Development Of NPS 1776 for Neurological Disorders
SALT LAKE CITY, June 28 /CNW/ -- NPS Pharmaceuticals, Inc. (Nasdaq: NPSP - news; Toronto: NX - news) and Abbott
Laboratories (NYSE: ABT - news) announced today that preclinical and clinical data on NPS 1776 were presented at the Fifth Eilat Conference on New Antiepileptic Drugs in Eilat, Israel. NPS 1776 is a new compound that may have potential in the management of neurological disorders. It was recently licensed from NPS Pharmaceuticals to Abbott Laboratories, giving Abbott exclusive worldwide rights for the further development and marketing of this compound.
(Photo: newscom.com )
In several validated preclinical models of seizures and epilepsy, NPS 1776 has exhibited anticonvulsant activity. Activity in these preclinical models is believed to be a predictor of clinical therapeutic benefit in epilepsy.
In one preclinical model, NPS 1776 was administered daily for four weeks, and no development of tolerance to its
anticonvulsant activity was found. The compound did not induce or inhibit drug metabolism, nor did it have significant protein-binding activity. These findings suggest a low potential for drug-to-drug interactions, and are encouraging for a compound in development for the treatment of epilepsy, since this condition is often managed with more than one anticonvulsant medication. These and other preclinical models suggested that NPS 1776 may also have potential therapeutic uses in other neurologic disorders.
Additionally, data were presented on two double-blind, placebo-controlled Phase I studies of healthy volunteers, conducted in the United Kingdom last year to evaluate single-dose and multiple-dose regimens. In the first Phase I study, a total of 18 volunteers were given an ascending dose of NPS 1776 ranging from 100 mg to 1600 mg three times daily. In the multiple-dose Phase I study, a total of 36 volunteers were given NPS 1776 for 10 days at three doses three times daily ranging from 1200 mg to 2400 mg. In both studies, NPS 1776 was well tolerated and there were no clinically important changes in vital signs, ECGs, clinical lab evaluations, or standard neurological exams.
CHris



To: Frostman who wrote (284)6/30/2000 10:16:01 AM
From: Skywatcher  Read Replies (2) | Respond to of 328
 
TAP withdraws impotence drug application
LAKE FOREST, Ill., June 30 (Reuters) - TAP Pharmaceutical Products Inc. said on Friday it was withdrawing the new drug application for its impotence drug Uprima and would resubmit it with new data at a later date.
TAP, a joint venture between Illinois-based Abbott Laboratories Inc. (NYSE:ABT - news) and Japan's Takeda Chemical Industries Ltd. , said it was withdrawing the application because it has additional data and continuing studies that could further establish the drug's safety and efficacy.
TAP licensed apomorphine HCl tablets, which it calls Uprima, from Pentech Pharmaceuticals Inc. of Deerfield, Ill.
I think this could be a positive if indeed the new information gives the drug application a lot more strength since it has been somewhat controversial up to this point.
chris



To: Frostman who wrote (284)11/3/2000 11:41:23 AM
From: Skywatcher  Respond to of 328
 
Premier Signs New Group Purchasing Contracts With Safety Needle Suppliers
Evaluated Needlestick Prevention Devices to Continue in Premier Product Catalog for the Alliance's Hospital Members
CHICAGO, Nov. 3 /PRNewswire/ -- Hospital members of Premier will continue to have group purchasing contracts in place
and options for several different hypodermic syringe devices with features intended to prevent needlesticks.
Premier, one of the nation's leading alliances of hospitals and health systems, has awarded new two-year group purchasing contracts for such products to three companies and continues an existing group contract in place with a fourth. The new contracts were effective Nov. 1.
The recently awarded new contracts cover hinge-technology needle sheathing devices offered by Safety Medical Supply
International, Inc. (SMSI) of Waltham, Mass., the single-use retractable syringes offered by New Medical Technology, Inc.
(NMT) of Zionsville, Ind., and the single-use retractable syringes offered by Abbott Laboratories of Abbott Park, Ill., though its marketing arrangement with Retractable Technologies, Inc. (RTI) of Little Elm, Texas.
In addition, Premier's earlier group purchasing contract with BD (Becton Dickinson) of Franklin Lakes, N.J., continues to make this company's family of safety syringes available to Premier members.
The group contracts for SMSI, NMT, and RTI products succeed 18-month contracts with these companies expiring Oct. 31.
The earlier contracts and the new contracts were developed through Premier's Breakthroughs Technology program which
seeks to identify new or evolving medical technology that can provide the full value of clinical efficacy, safety for patients and workers, and cost-effectiveness that Premier members have come to expect. During the term of these earlier contracts, several of Premier's members conducted a formal evaluation of the companies' products and reported findings to the companies and Premier.
The new contracts were recommended by a Premier committee of member representatives including, clinicians who reviewed
evaluation conclusions and current marketplace conditions such as state and federal legislative requirements relating to the use of safety devices by hospitals and healthcare workers.
Legislation recently approved by the U. S. Congress and expected to become law will strengthen protections for healthcare workers against needlestick injuries. While not specifying the adoption of any specific device, the legislation will require employers to evaluate the effectiveness of available technology. It also will require that frontline workers be involved in the evaluation, selection and implementation of new safety devices. The bill had broad support from healthcare industry organizations including Premier.
``The availability of syringes and needlestick protection devices continues to be a concern of Premier as the demand for them increases,'' said Gina Pugliese, director of the Premier Safety Institute. The demand has risen with increased recognition of the risks to healthcare workers presented by accidental sticks from sharps of all kinds, including hypodermic syringes, she said. The risks include transmission of bloodborne infections such as HIV and Hepatitis C.
``The four companies Premier contracts with are each pursuing safer workplaces and believe their products bring unique value to that objective, which we share,'' Pugliese added.
The expanded array of group purchasing contracts for safety devices is intended to support member hospitals' increasing efforts to prevent injuries from sharps, Pugliese said.
Premier member hospitals appear to be adopting and using safety devices at rates higher than available industry estimates for all hospitals, she reported, although sound data about usage and needlesticks unfortunately lags behind hospitals' great need for timely information. Premier is encouraging members to accelerate their needlestick prevention activities even further and share information about their experience with products and successful practices.
Also this month, Premier reported in a separate announcement that it had awarded additional new group purchasing agreements effective Nov. 1 for safety devices used in blood drawing (phlebotomy). Premier now has group contracts for such devices with BD, Bio-Plexus, Inc. of Vernon, Conn., SIMS Portex of Keene, N. H, MPS Acacia of Brea, Calif., and Abbott Laboratories, Inc., of Abbott Park, Ill., representative of the manufacturer, Retractable Technologies, Inc.
Abbott Laboratories (NYSE: ABT - news) is a global, diversified health care company devoted to the discovery, development, manufacture and marketing of pharmaceutical, diagnostic, nutritional and hospital products. It is the marketer and distributor for the patented needle safety devices manufactured by Retractable Technologies, Inc., a privately held company located in Little Elm, Texas. For more information, please visit www.Abbott.com and www.vanishpoint.com.
BD (Becton Dickinson) (NYSE: BDX - news) manufactures and sells a broad range of supplies, devices and systems for use
by health professionals, medical research institutions, industry and the general public. Operating internationally, the company is headquartered in Franklin Lakes, N. J. For more information, please visit www.bd.com.
New Medical Technology, Inc. is a subsidiary of NMT Group PLC located in Livingston, Scotland, with U.S. headquarters in Zionsville, Ind. The NMT Safety Syringe employs an automatic (or passive) retraction technology to prevent needlestick injury.
NMT Group PLC is a public company listed on AIM (Alternative Investment Market) in London. For more information,
please visit www.newmedicaltechnology.com.
Premier, Inc., is the parent company of a strategic alliance of 210 not- for-profit hospitals and healthcare systems across the United States. Premier's owners operate or have affiliation arrangements with approximately 1,850 hospitals. Premier's group purchasing program and supply chain management services are provided through Premier Purchasing Partners, L P. Electronic commerce support for Premier's group purchasing program is provided by medibuy. Premier is headquartered in San Diego, alif., with operations also located in Chicago, Ill., Charlotte, N. C., and Washington, D. C. For more information, please visit www.premierinc.com.
Looks like the ABBOTT boys are continuing good things and products for the hospital industry...there's LOT'S of money in these hospitals...and it certainly is a lot more stable than just having drugs in the pipeline.
chris